圣诺生物维培那肽原料药上市申请获批

Core Viewpoint - Shengnuo Biopharmaceutical has received approval from the National Medical Products Administration for the production of its active pharmaceutical ingredient, Vepagliflozin, which is aimed at treating type 2 diabetes and obesity [1] Company Summary - Shengnuo Biopharmaceutical's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has been granted a production approval notice for Vepagliflozin [1] - Vepagliflozin is a PEGylated form of Exenatide that activates GLP-1 receptors in the body, mimicking the physiological effects of natural human GLP-1 [1] Industry Summary - Vepagliflozin functions as a GLP-1 receptor agonist, enhancing insulin secretion in a glucose-dependent manner to lower blood sugar levels [1] - The drug is positioned to address the growing prevalence of type 2 diabetes and obesity, which are significant health concerns globally [1]